Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
View original at globenewswire.comPress Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Tzield slows disease progression by protecting the insulin-secreting beta cells of the pancreas
80% confidenceThe autoimmune attack that drives T1D in many cases begins early in life
80% confidenceTzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D if approved
80% confidenceBeta-cell mass is reduced by up to 95% in stage 4 T1D
80% confidenceThis priority review emphasizes the urgent need for innovative therapies like Tzield which has the potential to prevent the natural progression of T1D by delaying the loss of endogenous insulin production
80% confidenceIf approved, Tzield could represent an important advance for delaying the onset of stage 3 type 1 diabetes in early childhood, which would benefit patients and caregivers alike
80% confidence